ArticleJournal of clinical hypertension (Greenwich, Conn.)2015
Elevated Serum Level of Interleukin 17 in a Population With Prehypertension.
Article in Journal of clinical hypertension (Greenwich, Conn.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 50 citations in OpenAlex.
- Beta 2 adrenergic receptor gene methylation activates innate lymphoid cells to drive hypertension in lymphocyte deficient hosts.Cardiovascular research · 2025Article
- Immune mechanisms in the pathophysiology of hypertension.Nature reviews. Nephrology · 2024Review
- Meningeal interleukin-17-producing T cells mediate cognitive impairment in a mouse model of salt-sensitive hypertension.Nature neuroscience · 2024Article
- Psoriasis and Cardiometabolic Diseases: Shared Genetic and Molecular Pathways.International journal of molecular sciences · 2022Review
- Interleukin 17A: Key Player in the Pathogenesis of Hypertension and a Potential Therapeutic Target.Current hypertension reports · 2021Review
- Contribution of Th17 cells to tissue injury in hypertension.Current opinion in nephrology and hypertension · 2021Review
- T helper 17 cells in the pathophysiology of acute and chronic kidney disease.Kidney research and clinical practice · 2021Article
- A narrative review of prehypertension and the cardiovascular system: effects and potential pathogenic mechanisms.Annals of translational medicine · 2021Review
- Review
- Interleukin-17 signaling mediates cytolytic natural killer cell activation in response to placental ischemia.American journal of physiology. Regulatory, integrative and comparative physiology · 2020Article
- Pathogenic Pathways and Therapeutic Approaches Targeting Inflammation in Diabetic Nephropathy.International journal of molecular sciences · 2020Review
- Could IL-17A Be a Novel Therapeutic Target in Diabetic Nephropathy?Journal of clinical medicine · 2020Review
- Adaptive Immunity in Hypertension.Current hypertension reports · 2019Review
- Angiotensin II-induced hypertension and cardiac hypertrophy are differentially mediated by TLR3- and TLR4-dependent pathways.American journal of physiology. Heart and circulatory physiology · 2019Article
- Tissue Transglutaminase-Mediated AT1 Receptor Sensitization Underlies Pro-inflammatory Cytokine LIGHT-Induced Hypertension.American journal of hypertension · 2019Article
- Interleukin 17A Participates in Renal Inflammation Associated to Experimental and Human Hypertension.Frontiers in pharmacology · 2019Article
- Inflammation, Autoimmunity, and Hypertension: The Essential Role of Tissue Transglutaminase.American journal of hypertension · 2017Review
- Mechanistic rationales for targeting interleukin-17A in spondyloarthritis.Arthritis research & therapy · 2017Review
- Circulating Th1, Th2, and Th17 Levels in Hypertensive Patients.Disease markers · 2017Article
- Inhibition of Interleukin 17-A but not Interleukin-17F Signaling Lowers Blood Pressure and Reduces End-organ Inflammation in Angiotensin II-induced Hypertension.JACC. Basic to translational science · 2016Article
Corrections and comments
- Commented on by
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytokines play an important role in the pathogenesis of hypertension. The authors hypothesized that interleukin 17 (IL-17) might contribute to the prehypertensive state. This study evaluated the relationship between serum levels of IL-17 and prehypertension. A total of 394 participants were enrolled, after excluding for hypertension or treated hypertension, and divided into two groups (optimal blood pressure [BP] and prehypertension) based on the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure classification of BP. Optimal BP was defined as systolic BP <120 mm Hg and diastolic BP <80 mm Hg. Prehypertension was defined as systolic BP of 120 to 139 mm Hg or diastolic BP of 80 to 89 mm Hg. IL-17A levels were determined by enzyme-linked immunosorbent assay. The mean serum IL-17 concentration in the prehypertension group was significantly higher than in the optimal BP group. The cohort was divided into quartiles Q1 (≤3.5 ng/L), Q2 (3.60 to 6.10 ng/L), Q3 (6.20 to 10.00 ng/L), and Q4 (≥10.10 ng/L) based on IL-17 levels. The Q2 to Q4 groups had increasing odds ratios for having prehypertension compared with the Q1 group. Elevated serum IL-17 was accompanied by a rise in systolic BP. Thus, increased serum IL-17 levels are associated with prehypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.